Researchers at the Spanish Superior Scientific Research Council (CSIC) have successfully completed a small Phase I human clinical trial of an HIV vaccine candidate that granted 90 percent of 30 study participants an immunological response against the virus, Gizmag reports. “The MVA-B vaccine draws on the natural capabilities of the human immune system and ‘has proven to be as powerful as any other vaccine currently being studied, or even more,’ says Mariano Esteban, head researcher from CSIC’s National Biotech Centre,” the magazine writes (Borgobello, 9/28).
Maintaining Commitment Amid Promising Scientific Advances Is Necessary To Make AIDS Vaccine A Reality
In this Huffington Post opinion piece, Mitchell Warren, executive director of AVAC: Global Advocacy for HIV Prevention, examines the need for continued attention and funding for additional research for an AIDS vaccine, highlighting advancements presented at the AIDS Vaccine 2011 conference in Bangkok, Thailand earlier this month. He writes, “We don’t yet have a blueprint for an effective vaccine to roll-out. But, as presented this week in Bangkok, the complex success of the RV144 analysis, combined with a flurry of advances in understanding the development of broadly-neutralizing antibodies against HIV, show that the science of an AIDS vaccine is vibrant and vital. Now is exactly the time to maintain commitment.”
The Bill & Melinda Gates Foundation announced this week “that it is accepting proposals for Round 8 of its Grand Challenges Explorations, a $100 million grant initiative to encourage innovation in global health and development research,” according to a Gates Foundation press release. Topics include areas of agriculture, nutrition, immunization…
“The rotavirus vaccine introduced in Mexico in 2007 still appears to be preventing diarrhea-related deaths in children, despite speculation that years later the vaccine may not be as effective,” according to the Los Angeles Times’ “Booster Shots” blog. “In a letter released Wednesday in the New England Journal of Medicine, researchers report that the vaccine still seems to be successful in reducing mortality rates among children,” the blog writes, adding that rotavirus “is responsible for 527,000 childhood deaths per year” worldwide.
“Mexico plans to administer the vaccine against human papillomavirus (HPV), which can cause cervical cancer, to all girls beginning next year, the country’s health ministry said Tuesday,” Agence France-Presse reports. Health Minister Jose Angel Cordova “said while deaths from cervical cancer had fallen 47 percent in the country over the past two decades, there were still 13.4 cases for every 100,000 women last year,” AFP writes, adding, “Cervical cancer kills about 4,200 women in Mexico each year” (8/30).
Genetic Factor Found In Link Between H1N1 Flu Vaccine And Children's Narcolepsy, Finland Institute Says
“Finland’s national health institute said on Thursday its latest research on previously found links between children’s narcolepsy and GlaxoSmithKline’s [GSK] Pandemrix vaccine against [H1N1] swine flu also involved a genetic risk factor,” Reuters reports. In Finland, where 98 narcolepsy cases have been reported following the flu vaccinations, researchers found vaccinated children ages four to 19 “had a 12.7 times higher risk of experiencing narcolepsy than those who were not,” the news agency notes (9/1).
The U.N.’s Pan-American Health Organization, the United States and the international community “should be working with the Haitian Health Ministry to wage a more aggressive and effective effort” against the cholera epidemic that hit the country last year, and those efforts “should include not only clean water and sanitation systems but more antibiotics and cholera vaccinations,” a New York Times editorial says. “Ramping up manufacturing” of the cholera vaccine — of which there are less than 400,000 doses worldwide — “could be readily done and would have global benefits,” the editorial states.
Candidate Malaria Vaccine Represents 'Potentially Encouraging Anti-Malaria Strategy,' Researchers Say
A team of researchers led by Stephen Hoffman of Sanaria Inc. have created a candidate malaria vaccine against Plasmodium falciparum, the most deadly of the malaria parasites, using live but weakened parasites that “represents a potentially encouraging anti-malaria strategy,” an NIH/National Institute of Allergy and Infectious Diseases press release reports. The findings of the research, which “was conducted by scientists at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, working in concert with a large team of collaborators,” were published in Thursday’s online issue of Science, the press release states (9/8).
“With almost 30,000 cases of measles and eight deaths from the disease recorded in the European Union so far this year, a leading health official is urging doctors to do more to ensure parents have their children vaccinated with” the measles, mumps and rubella (MMR) vaccine, Reuters reports. Marc Sprenger, director of the European Center for Disease Prevention and Control (ECDC), “said MMR vaccine coverage rates across the region are currently around 90 percent, leaving significant groups such as children or young adults unprotected,” and that “it was crucial for pediatricians and family doctors to give balanced, evidence-based information to help parents decide on vaccinations,” Reuters writes.
In this report from the Center for Strategic and International Studies, released ahead of the GAVI Alliance pledging conference, authors Lisa Carty, J. Stephen Morrison, Margaret Reeves, and Amanda Glassman write, “Its many achievements notwithstanding, GAVI still needs a strategic approach in the coming years if it is to deepen…